Fang Frank Yu

Fang Frank Yu

Auto-generated profile, based on publicly available information

Fang Frank Yu

From the Department of Radiology (F.F.Y., N.S., P.S., K.R.), Advanced Imaging Research Center (F.F.Y., J.R.), Neurology (P.S., B.G.), UT Southwestern Medical Center, Dallas, TX, United States and UT Southwestern School of Medicine (E.J.), Dallas, TX, United States.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
CYChandan Ganesh Bangalore Yogananda
Chandan Ganesh Bangalore Yogananda
BSB.R. Shah
B.R. Shah
SNS.S. Nalawade
S.S. Nalawade
GMG.K. Murugesan
G.K. Murugesan
FYF.F. Yu
F.F. Yu
JMJ.A. Maldjian
J.A. Maldjian
Motivation Whole-genome DNA sequencing (WGS) enables the discovery of non-coding variants, but tools are lacking to prioritize the subset that functionally impacts human phenotypes. DNA sequence variants that disrupt or create transcription factor binding sites (TFBS) can modulate gene expression. find-tfbs efficiently scans phased WGS in large cohorts to identify and count TFBSs in regulatory sequences. This information can then be used in association testing to find putatively functional non-coding variants associated with complex human diseases or traits. Results We applied find-tfbs to discover functional non-coding variants associated with hematological traits in the NHLBI Trans-Omics for Precision Medicine (TOPMed) WGS dataset (Nmax=44,709). We identified >2000 associations at P<1×10−9, implicating specific blood cell-types, transcription factors and causal genes. The vast majority of these associations are captured by variants identified in large genome-wide association studies (GWAS) for blood-cell traits. find-tfbs is computationally efficient and robust, allowing for the rapid identification of non-coding variants associated with multiple human phenotypes in very large sample size. Availability https://github.com/Helkafen/find-tfbs and https://github.com/Helkafen/find-tfbs-demo Contacts sebastian.meric.de.bellefon@umontreal.ca and guillaume.lettre@umontreal.ca Supplementary information Supplementary data are available.

23 August 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
PCPetrice M. Cogswell
Petrice M. Cogswell
TATrevor J. Andrews
Trevor J. Andrews
JBJerome A. Barakos
Jerome A. Barakos
FBFrederik Barkhof
Frederik Barkhof
SBSuzie Bash
Suzie Bash
DGDementia Study Group
Dementia Study Group
With the full FDA approval and centers for Medicare & Medicaid services (CMS) coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment (MCI) or mild dementia due to amyloid-positive Alzheimer’s disease (AD). The goal of this paper is to provide updated practical considerations for radiologists, including implementation of MR imaging protocols, workflows and reporting and communication practices relevant to anti-amyloid immunotherapy and monitoring for amyloid-related imaging abnormalities (ARIA). Based on consensus discussion within an expanded ASNR Alzheimer’s, ARIA, and Dementia study group, we will: (1) summarize the FDA guidelines for evaluation of radiographic ARIA; (2) review the three key MRI sequences for ARIA monitoring and standardized imaging protocols based on ASNR-industry collaborations; (3) provide imaging recommendations for three key patient scenarios; (4) highlight the role of the radiologist in the care team for this population; (5) discuss implementation of MRI protocols to detect ARIA in diverse practice settings; and (6) present results of the 2023 ASNR international neuroradiologist practice survey on dementia and ARIA imaging. ABBREVIATIONS: AD = Alzheimer’s disease; ARIA = amyloid-related imaging abnormalities; APOE = apolipoprotein-E; CMS = centers for Medicare & Medicaid services; MCI = mild cognitive impairment.

15 June 2020 in Brain
Verified
Journal Article
Closed access
BSBhavya R Shah
Bhavya R Shah
VLVance T Lehman
Vance T Lehman
TKTimothy J Kaufmann
Timothy J Kaufmann
DBDaniel Blezek
Daniel Blezek
JWJeff Waugh
Jeff Waugh
RCRajiv Chopra
Rajiv Chopra
Magnetic resonance guided high intensity focused ultrasound is a novel, non-invasive, image-guided procedure that is able to ablate intracranial tissue with submillimetre precision. It is currently FDA approved for essential tremor and tremor dominant Parkinson’s disease. The aim of this update is to review the limitations of current landmark-based targeting techniques of the ventral intermediate nucleus and demonstrate the role of emerging imaging techniques that are relevant for both magnetic resonance guided high intensity focused ultrasound and deep brain stimulation. A significant limitation of standard MRI sequences is that the ventral intermediate nucleus, dentatorubrothalamic tract, and other deep brain nuclei cannot be clearly identified. This paper provides original, annotated images demarcating the ventral intermediate nucleus, dentatorubrothalamic tract, and other deep brain nuclei on advanced MRI sequences such as fast grey matter acquisition T1 inversion recovery, quantitative susceptibility mapping, susceptibility weighted imaging, and diffusion tensor imaging tractography. Additionally, the paper reviews clinical efficacy of targeting with these novel MRI techniques when compared to current established landmark-based targeting techniques. The paper has widespread applicability to both deep brain stimulation and magnetic resonance guided high intensity focused ultrasound.

11 March 2015 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
FYFang Yu
Fang Yu
DBDaniel S. Barron
Daniel S. Barron
BTBundhit Tantiwongkosi
Bundhit Tantiwongkosi
PFPeter Fox
Peter Fox
Background and Purpose: Accurate diagnosis of Atypical Parkinsonian Syndromes (APS) is important due to differences in prognosis and management, but remains a challenge in the clinical setting. The purpose of our meta‐analysis was to identify characteristic patterns of gray matter atrophy in Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), Multisystem‐Atrophy Parkinsonian type (MSA‐P), and Idiopathic Parkinson's Disease (IPD).Materials and Methods: Whole‐brain meta‐analysis was performed on 39 published voxel‐based morphometry (VBM) articles (consisting of 404 IPD, 87 MSA‐P, 165 CBD, and 176 PSP subjects) using the modified Anatomic Likelihood Estimation method. Based on these results, contrast analyses were then utilized to determine areas of atrophy shared by as well as unique to each disorder.Results: CBD was characterized by asymmetric gray matter atrophy in multiple cortical regions, while the thalamus‐midbrain and insula were predominantly involved in PSP. The striatum and superior cerebellum were affected in MSA‐P, while IPD demonstrated an anterior cerebral pattern. Although there was a mild overlap among PSP, CBD, and MSA‐P, significant regions of atrophy unique to each disorder were identified, including (1) the superior parietal lobule in CBD (2) putamen in MSA‐P (3) insula and medial dorsal nucleus in PSP.Conclusion: Our results suggest that there are characteristic patterns of atrophy in APS. Guided by these findings, future studies on the individual subject level may lead to the development of robust imaging biomarkers.

6 November 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
FYF. Yu
F. Yu
QFQ. Fan
Q. Fan
QTQ. Tian
Q. Tian
CNChanon Ngamsombat
Chanon Ngamsombat
NMN. Machado
N. Machado
SHS.Y. Huang
S.Y. Huang
BACKGROUND AND PURPOSE: Remyelination represents an area of great therapeutic interest in multiple sclerosis but currently lacks a robust imaging marker. The purpose of this study was to use high-gradient diffusion MRI and macromolecular tissue volume imaging to obtain estimates of axonal volume fraction, myelin volume fraction, and the imaging g-ratio in patients with MS and healthy controls and to explore their relationship to neurologic disability in MS. MATERIALS AND METHODS: Thirty individuals with MS (23 relapsing-remitting MS, 7 progressive MS) and 19 age-matched healthy controls were scanned on a 3T MRI scanner equipped with 300 mT/m maximum gradient strength using a comprehensive multishell diffusion MRI protocol. Macromolecular tissue volume imaging was performed to quantify the myelin volume fraction. Diffusion data were fitted to a 3-compartment model of white matter using a spheric mean approach to yield estimates of axonal volume fraction. The imaging g-ratio was calculated from the ratio of myelin volume fraction and axonal volume fraction. Imaging metrics were compared between groups using 2-sided t tests with a Bonferroni correction. RESULTS: The mean g-ratio was significantly elevated in lesions compared with normal-appearing WM (0.74 vs 0.67, P < .001). Axonal volume fraction (0.17 vs 0.23, P < .001) and myelin volume fraction (0.17 vs 0.25, P < .001) were significantly lower in lesions than normal-appearing WM. Myelin volume fraction was lower in normal-appearing WM compared with that in healthy controls (0.25 vs 0.27, P = .009). Disability, as measured by the Expanded Disability Status Scale, was significantly associated with myelin volume fraction (β = –40.5, P = .001) and axonal volume fraction (β = –41.0, P = .016) in normal-appearing WM. CONCLUSIONS: The imaging g-ratio may serve as a biomarker for the relative degree of axonal and myelin loss in MS.

12 December 2018 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
FYFang F. Yu
Fang F. Yu
FCFlorence L. Chiang
Florence L. Chiang
NSNicholas Stephens
Nicholas Stephens
SHSusie Y. Huang
Susie Y. Huang
BBBerkin Bilgic
Berkin Bilgic
RRRebecca Romero
Rebecca Romero